Article
Oncology
Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, Donatella Gambini, Concetta Blundo, Letterio Runza, Stefano Ferrero, Elena Guerini-Rocco, Nicola Fusco
Summary: The loss of PTEN is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer patients. Patients with PTEN-low tumors showed significantly enriched hormone receptor negativity and HER2 negativity compared to those with PTEN-retained tumors. The combined analysis of PTEN, HER2, and hormone receptor status provides relevant information for a more precise risk assessment of patients with breast cancer.
Review
Oncology
Arya Mariam Roy, Vasanthan Muthusamy Kumarasamy, Ajay Dhakal, Ruth O'Regan, Shipra Gandhi
Summary: The expansion of HER2-status to HER2-low has made a major impact in oncology. HER2-low expression has become a targetable biomarker and trastuzumab deruxtecan has shown significant survival benefit in metastatic HER2-low breast cancer. Treatment algorithms for hormone receptor-positive and triple-negative BC need to be reconsidered, and a treatment sequencing algorithm for HER2-low BC based on clinical evidence is proposed in this article.
Article
Oncology
Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Summary: The expression of HER2-low-positive shows high instability from primary breast cancer to residual disease after neoadjuvant treatment. HER2-low-positive expression in residual disease may guide personalized adjuvant treatment for high-risk patients in clinical trials.
Article
Multidisciplinary Sciences
Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Yongguang Yang, Marissa Leonard, Zhenhua Luo, Syn Yeo, Gregory Bick, Mingang Hao, Chunmiao Cai, Mahmoud Charif, Jiang Wang, Jun-Lin Guan, Elyse E. Lower, Xiaoting Zhang
Summary: The study reveals the crucial role of MED1 in HER2-driven mammary tumorigenesis, showing that its overexpression can significantly promote the onset, growth, metastasis, and multiplicity of HER2 tumors. Further investigations demonstrate that MED1 is involved in epithelial-mesenchymal transition, cancer stem cell formation, and response to anti-HER2 therapy. Additionally, the research identifies Jab1 as the key target gene of MED1 contributing to these processes and shows a reciprocal regulation between Jab1 and MED1.
Review
Oncology
William Sebastian, Lauren Forchette, Kelsey Donoughe, Yibei Lun, Anisha Verma, Tuoen Liu
Summary: In this review paper, various important aspects of hormone receptor (HR)-positive breast cancer were discussed, including HR structure and signaling, genetics (epigenetics and gene mutations), gene expression-based assays, traditional and new drugs for treatment, and new technological uses in diagnosis and treatment. Particularly, the commonly mutated genes and abnormally methylated genes in HR-positive breast cancer were summarized, and the common gene expression-based assays used in breast cancer as prognostic and/or predictive tools were compared in detail. These topic discussions have not been fully described and summarized within other research or review articles.
Article
Multidisciplinary Sciences
Anna Adam-Artigues, Enrique J. Arenas, Alex Martinez-Sabadell, Fara Braso-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, Maria Teresa Martinez, Juan Carbonell-Asins, Soraya Simon, Jesus Poveda, Santiago Moragon, Sandra Zazo, Debora Martinez, Ana Rovira, Octavio Burgues, Federico Rojo, Joan Albanell, Begona Bermejo, Ana Lluch, Aleix Prat, Joaquin Arribas, Pilar Eroles, Juan Miguel Cejalvo
Summary: AXL overexpression is identified as an essential mechanism of trastuzumab resistance in HER2-positive breast cancer, and targeting AXL can restore trastuzumab response. AXL may serve as a predictive biomarker for prognosis in HER2-positive breast cancer patients. The study emphasizes the importance of targeting AXL in combination with anti-HER2 drugs to overcome resistance.
Article
Plant Sciences
Jun Takeuchi, Kosuke Fukui, Yoshiya Seto, Yousuke Takaoka, Masanori Okamoto
Summary: Small-molecule plant hormones play a crucial role in controlling plant growth, development, differentiation, and environmental responses. Through genomic decoding of model plants with genetic mutants, scientists have elucidated the molecular mechanisms of nine types of plant hormones and identified the structure of hormone receptors. Studies on the three-dimensional structure of ligand-receptor complexes have revealed the details of ligand perception mechanisms.
Review
Biochemistry & Molecular Biology
Benoite Mery, Coralie Poulard, Muriel Le Romancer, Olivier Tredan
Summary: The AKT protein kinase has a key role in breast cancer, particularly in hormone receptor-positive breast cancer, where hyperactivation of the PI3K/AKT signaling pathway leads to treatment resistance. AKT inhibitors and PI3K/mTOR inhibitors have been developed and approved for the treatment of this type of breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Ioannis A. Voutsadakis
Summary: This study investigates ER-positive/HER2-negative or luminal breast cancers with high mutation numbers and compares them with cancers of the same subtype and low mutation numbers. The results show that breast cancers with high mutation numbers have a higher prevalence of certain genetic mutations and DNA damage response genes. However, the prognosis of these breast cancers is not significantly different compared to those with lower mutation counts. These findings provide information on the suitability of these cancers for immunotherapy and potential combination therapies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Chemistry, Medicinal
Lilan Xin, Jian Min, Hebing Hu, Yuanyuan Li, Chuanqian Du, Baohua Xie, Yan Cheng, Xiaofei Deng, Xiangping Deng, Kang Shen, Jian Huang, Chun -Chi Chen, Rey-Ting Guo, Chune Dong, Hai -Bing Zhou
Summary: In this study, a novel class of dual-targeting selective estrogen receptor degraders (SERDs) based on a three-dimensional oxabicycloheptene sulfonamide (OBHSA) scaffold equipped with aromatase inhibitor (AI) activity were identified. These compounds showed excellent ERa degradation activity, ARO inhibitory activity, and antiproliferative activity against drug-resistant breast cancer cells.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Hengqiang Zhao, Yiping Gong
Summary: Single estrogen receptor (ER)+ and progesterone receptor (PR)+ tumors account for about 10% of all breast cancers. The prognosis of these tumors varies based on HER2 status, with single ER+ and PR+ patients showing different survival outcomes in different HER2 subtypes. In HER2- subtype, single PR+ patients had poorer prognoses than single ER+ patients, while in HER2+ subtype, single ER+ and PR+ patients showed similar prognoses compared with ER-PR- patients.
FRONTIERS IN ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Jiaqi Yao, Yiran Tao, Zelin Hu, Junjie Li, Ziyi Xue, Ya Zhang, Yi Lei
Summary: This paper provides a comprehensive review of ER's structural functions and highlights the recent advancements in novel drugs targeting ER, namely SERD and SERCA, focusing on their structural optimization strategies and future directions. It also discusses the therapeutic potential and challenges of these drugs in breast cancer and other ER-related diseases.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Zhengxing Zhou, Chengmin Zhang, Zhiyuan Ma, Hu Wang, Biguang Tuo, Xiaoming Cheng, Xuemei Liu, Taolang Li
Summary: Breast cancer is the most common malignant tumor in women, with HER2-positive breast cancer being treatable using targeting strategies for HER2. Although there has been significant progress, challenges such as recurrence, metastasis, and drug resistance remain. Dysfunction of ion channels and transporters may serve as new therapeutic targets.
CANCER GENE THERAPY
(2022)
Article
Oncology
Matthew Loft, Sheau Wen Lok, Richard De Boer, Laeeq Malik, Sally Greenberg, Belinda Yeo, Angelyn Anton, Michelle Nottage, Vanessa Wong, Louise Nott, Ian M. M. Collins, Javier Torres, Frances Barnett, Janine M. M. Lombard, Peter Gibbs, Lucy Gately
Summary: The study aimed to investigate the efficacy of combining endocrine therapy (ET) with dual anti-HER2 targeted therapy and chemotherapy in HER2 + /HR + breast cancer patients. The results showed that adding ET during first-line chemotherapy in combination with dual anti-HER2 therapy significantly improved 5-year progression-free survival (PFS) and overall survival (OS), with no significant safety concerns.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Biotechnology & Applied Microbiology
Gloria Yang-Kolodji, Shannon M. Mumenthaler, Arjun Mehta, Lingyun Ji, Debu Tripathy
Article
Biochemistry & Molecular Biology
Y. G. Lin, J. Shen, E. Yoo, R. Liu, H-Y Yen, A. Mehta, A. Rajaei, W. Yang, P. Mhawech-Fauceglia, F. J. DeMayo, J. Lydon, P. Gill, A. S. Lee
Article
Radiology, Nuclear Medicine & Medical Imaging
Laurie L. Brunette, Shahram Bonyadlou, Lingyun Ji, Susan Groshen, Dena Shuster, Arjun Mehta, Richard Sposto, Koji Matsuo, Yvonne G. Lin, Lynda D. Roman
CLINICAL NUCLEAR MEDICINE
(2018)
Review
Pathology
Cristina Costales, Arjun Mehta, Sujit Kulkarni, Brent K. Larson
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
(2019)